Using clinical lab data to improve diabetes outcomes in underserved populations

More than 37 million Americans (more than 11% of the population) have diabetes.1 This statistic alone highlights the need to improve patient care, especially in underserved populations where incidence of the disease is high.

Understanding my digestive health: Celiac disease, wheat allergy and non-celiac gluten sensitivity

Celiac disease is an autoimmune disorder that causes genetically susceptible individuals to react to gluten—a protein found in wheat, barley and rye. Individuals with an allergy to wheat have a different type of immune reaction to wheat proteins. For those with a non-celiac gluten sensitivity, consumption of gluten can cause discomfort and other symptoms, although the causes are not yet clearly identified. Even though the three conditions are quite different, they may be confused because they can all result in some overlapping symptoms after consuming gluten. 

Chronic kidney disease and my journey as a two-time kidney transplant recipient

I’d like to introduce you to Cindy, my kidney transplant. Named after the nurse who tended to me in the hospital, Cindy has been with me since 2007. I tell people that Cindy calls the shots—and I work hard to manage my health, stay connected with my healthcare providers and make sure that she stays happy. It’s not easy, but I’m grateful that I have a functioning kidney, and that’s why I’m sharing my chronic kidney disease (CKD) journey to help both patients and their providers.

Physical activity helps employees to manage and even reduce risk of diabetes

As you’ve probably heard, many chronic diseases can be managed or outright prevented with physical activity. When it comes to diabetes, enabling employees to become more active through regular activity delivers a host of benefits.

Why health coaching belongs in diabetes prevention

At Labcorp, we believe chronic diseases like diabetes can be prevented by efficient and comprehensive health coaching. That’s why we’re passionate about guiding employees on the path toward their best life. Whether the goal is creating general well-being or managing preexisting conditions, we meet employees where they are and help them meet their overall health and wellness goals.

Preparation, prevention: Screening for prediabetes before it gets worse

This Diabetes Awareness Month, we’re committed to helping you gain a better understanding of your health so you can take action. It is estimated that nearly 96 million U.S. adults have prediabetes, and more than 8 in 10 people do not realize they have it. Prediabetes, often reversible with healthy lifestyle changes, can cause health complications if left untreated or unmanaged. It can lead to Type 2 diabetes, heart disease, stroke, chronic kidney disease (CKD), colorectal cancer (CRC) and more.

How one company used lab data insights to improve population management of chronic kidney disease (CKD)

When one of New Jersey’s largest independent physician associations (IPA) entered into a value-based care contract, they intensified their focus on identifying and managing their chronic kidney disease (CKD) population with a few goals in mind:

Labcorp launches first-of-its-kind at-home collection device for diabetes risk testing

BURLINGTON, N.C. --(BUSINESS WIRE)--May 16, 2022-- There is a new and convenient way for millions of individuals to assess whether they are at risk for developing diabetes.

Siemens Healthineers launches Enhanced Liver Fibrosis (ELF) test in the U.S.

TARRYTOWN, N.Y., Jan. 26, 2022 —The Enhanced Liver Fibrosis (ELF) Test from Siemens Healthineers is now available in the United States, providing broad clinical access to the minimally invasive prognostic tool. Currently, the ELF Test is exclusively available through collaborations with Labcorp (NYSE: LH) and Quest Diagnostics (NYSE: DGX), providing access (with a physician’s order) across the country. This is the first time the test is commercially available in the U.S., following De Novo marketing authorization from the U.S. Food and Drug Administration (FDA) in August 2021.

Labcorp to offer risk-scoring test for people with advanced liver fibrosis due to NASH

BURLINGTON, N.C. --(BUSINESS WIRE)--Jan. 26, 2022-- For the millions of people in the United States living with an advanced form of chronic liver disease, simply understanding the potential for future complications could help stave off severe damage and even a transplant. Labcorp (NYSE: LH), a leading global life sciences company, is making this possible by offering the Enhanced Liver Fibrosis (ELF™) test. Developed by Siemens Healthineers, the physician-ordered blood test helps assess the risk of disease progression in individuals—opening the door for improved outcomes. The test has been granted De Novo marketing authorization by the U.S. Food and Drug Administration .